MORGAN STANLEY PLC/CALL/ABBVIE/260/0.1/20.06.25 Stock

Warrant

DE000ME8F6K4

Real-time Bid/Ask 08:00:07 2024-06-05 EDT
0.084 EUR / 0.091 EUR +8.64% Intraday chart for MORGAN STANLEY PLC/CALL/ABBVIE/260/0.1/20.06.25
Current month+8.00%
1 month-16.49%
Date Price Change
24-06-05 0.08 -1.23%
24-06-04 0.081 +3.85%
24-06-03 0.078 +4.00%
24-05-31 0.075 0.00%
24-05-30 0.075 -1.32%

Delayed Quote Börse Stuttgart

Last update June 05, 2024 at 05:52 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
Issuer Morgan Stanley
WKN ME8F6K
ISINDE000ME8F6K4
Date issued 2024-02-08
Strike 260 $
Maturity 2025-06-20 (380 Days)
Parity 10 : 1
Emission price 0.12
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.27
Lowest since issue 0.061
Delta0.06x
Omega 9.519
Premium60.96x
Gearing166.71x
Moneyness 0.6236
Difference Strike 97.86 $
Difference Strike %+37.64%
Spread 0.019
Spread %19.19%
Theoretical value 0.0870
Implied Volatility 26.24 %
Total Loss Probability 96.72 %
Intrinsic value 0.000000
Present value 0.0870
Break even 260.95 €
Theta-0x
Vega0.02x
Rho0.01x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
162.1 USD
Average target price
183 USD
Spread / Average Target
+12.89%
Consensus